Embryonic stem cell therapy-Eye disorders - Regenerative Patch Technologies

Drug Profile

Embryonic stem cell therapy-Eye disorders - Regenerative Patch Technologies

Alternative Names: CPCB-RPE1; hESC-RPE Synthetic Substrate Patch

Latest Information Update: 11 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator California Institute of Technology/CalTech; University of California, Santa Barbara; University of Southern California
  • Developer Regenerative Patch Technologies
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Dry age-related macular degeneration

Most Recent Events

  • 04 Apr 2018 Efficacy and pharmacodynamics data from phase I/II trial in Dry age related macular degeneration released by Regenerative Patch Technologies
  • 13 Apr 2016 Immunogenicity data from preclinical studies in Dry age-related macular degeneration released by Regenarative Patch Technology
  • 01 Oct 2015 Phase-I/II clinical trials in Dry Age-related macular degeneration in USA (Intraocular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top